Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161441 · ClinicalTrials.gov registry record · Phase 2
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
A Phase 2 study of Resectable Non-Small-Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT06161441: Active Phase 2 study of Resectable Non-Small-Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.
NCT06161441 is a Phase 2 study of Resectable Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 195 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161441, a Phase 2 study of Resectable Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is in comparison with cemiplimab and chemotherapy as peri-operative therapy in participants with NSCLC. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * How administering the study drugs might affect quality of life
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cemiplimab
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Fianlimab
Study Locations (20)
Victoria
- Eastern Health - Box Hill
- St Vincent's Hospital - Fitzroy
Nouvelle-Aquitaine
- Centre Hospitalier Universitaire (CHU) Bordeaux - Bordeaux
- CHU Limoges - Limoges
Florida
- Clermont Oncology Center - Clermont
Illinois
- University of Illinois - Chicago
Kansas
- University of Kansas Cancer Center-Westwood - Westwood
Michigan
- Henry Ford Health System - Detroit
Missouri
- Mercy South - St Louis
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2024-07-16 |
| Est. Completion | 2029-11-04 |
| Phase | Phase 2 |
What the registry record for NCT06161441 still lists
NCT06161441 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% higher).
The record links to 1 condition, with Resectable Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06161441 names 20 study sites across 18 states, led by Victoria, Nouvelle-Aquitaine, Florida.
Frequently Asked Questions
What is clinical trial NCT06161441 about?
NCT06161441 is a clinical study titled "A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery". This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in...
What is the current status of trial NCT06161441?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2024-07-16. Estimated completion is 2029-11-04.
What conditions does trial NCT06161441 study?
This clinical trial studies the following conditions: Resectable Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT06161441?
The interventions under investigation include: Carboplatin (DRUG), Cemiplimab (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT06161441?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161441 being conducted?
This trial has 20 study locations across Florida, Illinois, Kansas, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06161441's enrollment target sits among peer trials
195 350th of 2000 higher than 1,649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI